NSABP FC-6: Surgical conversion rate in colorectal cancer patients with unresectable, KRAS wild-type liver metastases receiving mFOLFOX7 plus cetuximab View External Link Categories Peer Reviewed Publications Topics: Cetuximab FOLFOX7 KRAS metastatic colorectal cancer CRC OBP